

China

Tuberculosis profile

Population 2016

1 404 million

Estimates of TB burden*, 2016	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	50 (34–70)	3.6 (2.4–5)
Mortality (HIV+TB only)	1.8 (0.7–3.4)	0.13 (0.05–0.24)
Incidence (includes HIV+TB)	895 (766–1 030)	64 (55–74)
Incidence (HIV+TB only)	11 (6.9–15)	0.76 (0.49–1.1)
Incidence (MDR/RR-TB)**	73 (56–89)	5.2 (4–6.4)

Estimated TB incidence by age and sex (thousands)*, 2016

	0-14 years	> 14 years	Total
Females	47 (40–54)	245 (208–281)	292 (248–336)
Males	53 (45–61)	550 (468–633)	603 (513–694)
Total	100 (85–115)	795 (676–914)	895 (766–1 030)

TB case notifications, 2016

Total cases notified	783 842
Total new and relapse	778 493
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	43%
- % pulmonary	95%
- % bacteriologically confirmed among pulmonary	31%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2016	87% (75–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2016	0.06 (0.04–0.08)

TB/HIV care in new and relapse TB patients, 2016

	Number	(%)
Patients with known HIV-status who are HIV-positive	4 612	1%
- on antiretroviral therapy	4 051	88%

Drug-resistant TB care, 2016	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			58 000 (47 000–69 000)
Estimated % of TB cases with MDR/RR-TB	7.1% (5.6–8.7)	24% (20–28)	
% notified tested for rifampicin resistance	13%	55%	118 219
MDR/RR-TB cases tested for resistance to second-line drugs			
Laboratory-confirmed cases		MDR/RR-TB: 10 898, XDR-TB: 525	
Patients started on treatment ****		MDR/RR-TB: 5 405, XDR-TB: 265	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2015	94%	798 281
Previously treated cases, excluding relapse, registered in 2015	83%	5 739
HIV-positive TB cases registered in 2015	87%	2 444
MDR/RR-TB cases started on second-line treatment in 2014	41%	2 846
XDR-TB cases started on second-line treatment in 2014	32%	135

TB preventive treatment, 2016

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2017

National TB budget (US\$ millions)	384
Funding source: 96% domestic, 3% international, 1% unfunded	


* Ranges represent uncertainty intervals

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history


**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence
— Notified (new and relapse)
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2016




■ Females ■ Males

Treatment success rate (%)



— New and relapse
— Retreatment, excluding relapse
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)



■ Unfunded
■ Funded internationally
■ Funded domestically